RAPID Real‑World Dupixent Data Could Extend Regeneron and Sanofi’s Asthma Edge
Regeneron Pharmaceuticals (REGN), Sanofi (SNYNF) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
The RAPID registry from Regeneron and Sanofi tracks how real patients with asthma start and use Dupixent in everyday care. It aims to describe who gets the drug, how they use it over time, and what long‑term results and safety look like outside of controlled trials.
The treatment in focus is Dupixent, a biologic drug already approved for asthma and other type 2 inflammatory diseases. In this study, doctors prescribe Dupixent as part of normal care, and the registry simply follows what happens without changing treatment decisions.
The design is observational and prospective, meaning patients are followed forward in time after starting Dupixent. There is no random assignment, blinding, or protocol‑driven intervention, so the goal is to mirror real‑world practice rather than test Dupixent against a control drug.
The target follow‑up period is about three years, long enough to see sustained outcomes and safety patterns. The study has completed enrollment and follow‑up, and the record was most recently updated on June 3, 2026, signaling fresh data and renewed investor focus.
For investors, this update reinforces the durability of the Dupixent asthma franchise for Regeneron (REGN) and Sanofi (SNYNF) by adding real‑world evidence that can support broader use and pricing power. Strong registry results could strengthen their edge over rival biologics in asthma and related inflammatory diseases, potentially supporting sentiment and valuation as label expansions and guideline changes are considered.
The RAPID registry is now completed with updated information posted, and further details are available on the ClinicalTrials portal.
To learn more about REGN’s potential, visit the Regeneron Pharmaceuticals drug pipeline page.
